/
Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, we, our, Abeona or the Company ), is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Food and Drug Administration ( FDA ) approved ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets, also known as ZEVASKYN , as the first and only…
The business is unprofitable at the operating level (-1536.91% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$84M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$6M
Net Income (TTM)
$66M
▲ +211.7% YoY
Op. Margin
-1536.91%
ROIC
-39.86%
▲ +60.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$85M
▼ -44.2% YoY
Op. Cash Flow (TTM)
-$78M
▼ -36.3% YoY
Net Debt
-$145M
Net Cash Position
Cash & Equiv.
$168M
5Y CAGR: +14.2%
Continue Research